Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Phase 4TerminatedNCT00455364

University of Chicago20 enrolled

Overview

The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Infection

Interventions

VoriconazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old. * Patients must be able to give informed consent prior to and again after transplantation Exclusion Criteria: * Lung transplant patients unable to give informed consent. * Prior adverse reaction to the drug itraconazole or voriconazole

Locations (1)

The University of Chicago

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Subject will be monitored for any fungal infection throughout the duration of the study.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.